…
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -52.32M | -340.74M | -651.30M | -969.25M | -795.80M |
| Net income | -53.84M | -346.63M | -653.69M | -971.23M | -796.70M |
| Selling general administrative | - | 261.64M | 437.82M | 568.28M | 490.26M |
| Selling and marketing expenses | - | 190.90M | 247.71M | 370.29M | 303.10M |
| Gross profit | 391.94M | 362.40M | 363.23M | 380.04M | 364.15M |
| Reconciled depreciation | - | 52.20M | 133.40M | 124.10M | 47.77M |
| Ebit | -53.35M | -322.43M | -651.30M | -980.41M | -797.06M |
| Ebitda | -43.05M | -270.23M | -517.90M | -981.96M | -793.41M |
| Depreciation and amortization | 10.30M | 52.20M | 133.40M | -1.55M | 3.66M |
| Operating income | -53.35M | -357.56M | -669.32M | -980.41M | -797.06M |
| Other operating expenses | 578.22M | 873.38M | 1206.76M | 1543.64M | 1304.93M |
| Interest expense | 0.03M | - | 0.00M | -11.16M | 1.54M |
| Tax provision | - | 5.88M | 3.22M | 1.99M | 0.90M |
| Interest income | - | 12.21M | 15.26M | 9.46M | 3.46M |
| Net interest income | - | 12.21M | 15.26M | 9.46M | 1.92M |
| Income tax expense | 1.51M | 5.88M | 2.39M | 1.99M | 0.90M |
| Total revenue | 524.87M | 515.82M | 537.43M | 563.24M | 507.86M |
| Total operating expenses | 445.29M | 719.96M | 1032.55M | 1360.45M | 1161.21M |
| Cost of revenue | 132.93M | 153.42M | 174.21M | 183.20M | 143.72M |
| Total other income expense net | 1.03M | 16.82M | 18.02M | 11.16M | 1.27M |
| Net income from continuing ops | - | -346.63M | -707.70M | -971.23M | -796.70M |
| Net income applicable to common shares | - | - | - | -971.23M | -796.70M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 820.90M | 885.30M | 1040.00M | 1587.47M | 2278.59M |
| Intangible assets | - | 0.42M | 0.96M | 0.16M | 5.15M |
| Other current assets | 18.62M | 29.56M | 2.80M | 51.46M | 60.28M |
| Total liab | 285.29M | 304.48M | 271.59M | 429.13M | 433.28M |
| Total stockholder equity | 535.60M | 580.83M | 768.41M | 1158.34M | 1845.31M |
| Other current liab | 81.50M | 75.04M | 104.94M | 173.83M | 127.89M |
| Common stock | 0.14M | 0.14M | 0.14M | 0.14M | 0.14M |
| Capital stock | - | 0.14M | 0.14M | 0.14M | 0.14M |
| Retained earnings | -4258.32M | -4200.26M | -3853.64M | -3199.95M | -2228.71M |
| Other liab | - | - | - | 4.12M | 11.78M |
| Good will | 0.28M | - | - | 1.82M | - |
| Other assets | 0.00M | - | - | 26.00M | 45.14M |
| Cash | 481.39M | 519.85M | 615.10M | 905.45M | 1431.32M |
| Total current liabilities | 247.14M | 266.30M | 263.36M | 411.45M | 372.18M |
| Current deferred revenue | 107.89M | 118.49M | 131.73M | 149.44M | 143.84M |
| Net debt | -438.25M | -467.53M | -602.77M | -854.66M | -1344.63M |
| Short term debt | 16.97M | 24.57M | 8.63M | 37.24M | 37.37M |
| Short long term debt | - | - | - | - | 2.37M |
| Short long term debt total | 43.15M | 52.32M | 12.32M | 50.79M | 86.69M |
| Other stockholder equity | 4956.02M | 4938.99M | 4783.44M | 4523.87M | 4280.96M |
| Property plant equipment | - | - | - | 300.03M | 406.44M |
| Total current assets | 739.06M | 776.62M | 884.10M | 1258.76M | 1820.95M |
| Long term investments | - | 0.00M | 0.34M | 0.69M | 0.91M |
| Net tangible assets | - | - | - | 1156.36M | 1840.16M |
| Short term investments | - | 6.14M | 13.40M | 0.00M | 63.76M |
| Net receivables | 182.03M | 173.45M | 167.81M | 151.71M | 134.59M |
| Inventory | 57.01M | 53.76M | 69.02M | 130.32M | 123.21M |
| Accounts payable | 40.77M | 33.75M | 18.06M | 50.95M | 63.08M |
| Accumulated other comprehensive income | -162.24M | -158.05M | -161.53M | -165.72M | -207.07M |
| Non currrent assets other | 7.64M | 7.93M | 5.09M | 26.00M | 45.14M |
| Non current assets total | 81.84M | 108.69M | 155.91M | 328.70M | 457.64M |
| Capital lease obligations | - | 52.32M | 12.32M | 50.79M | 84.31M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -4.41M | -14.01M | -7.46M | 81.70M |
| Change to liabilities | - | - | - | 22.06M | 63.10M |
| Total cashflows from investing activities | -4.39M | -4.41M | -9.30M | -7.46M | 81.70M |
| Net borrowings | 1.90M | 0.00M | 0.00M | -2.37M | -44.81M |
| Total cash from financing activities | 1.90M | -0.07M | -48.83M | -86.24M | -52.90M |
| Change to operating activities | - | - | - | 30.60M | -8.73M |
| Net income | -55.35M | -346.63M | -653.69M | -971.23M | -796.70M |
| Change in cash | -41.07M | -93.05M | -310.05M | -513.84M | -486.09M |
| Begin period cash flow | 522.16M | 615.22M | 925.27M | 1439.11M | 1925.21M |
| End period cash flow | 481.09M | 522.16M | 615.22M | 925.27M | 1439.11M |
| Total cash from operating activities | -28.44M | -92.26M | -255.78M | -456.81M | -477.89M |
| Issuance of capital stock | - | - | - | 0.00M | 0.00M |
| Depreciation | 21.76M | 52.20M | 133.40M | 124.10M | 47.77M |
| Other cashflows from investing activities | 0.86M | 1.01M | -1.20M | - | 81.70M |
| Change to inventory | 2.50M | 2.51M | 57.28M | 11.20M | -67.00M |
| Change to account receivables | -33.23M | -26.80M | -12.39M | -21.50M | -18.93M |
| Sale purchase of stock | 0.00M | -0.07M | -6.98M | -71.83M | -4.27M |
| Other cashflows from financing activities | - | - | -41.85M | -12.03M | -3.82M |
| Change to netincome | - | - | - | 401.49M | 318.81M |
| Capital expenditures | 5.25M | 5.98M | 9.38M | 62.03M | 213.45M |
| Change in working capital | -59.39M | -36.53M | -52.16M | 6.33M | -62.40M |
| Stock based compensation | 13.88M | 155.62M | 260.72M | 326.78M | 282.43M |
| Other non cash items | 50.65M | 83.08M | 55.94M | 57.22M | 35.61M |
| Free cash flow | -33.69M | -98.24M | -265.17M | -518.84M | -691.33M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BNR Burning Rock Biotech Ltd |
0.35 2.80% |
12.85 | - | - | 0.24 | 1.62 | 0.85 | -0.17 |
| TMO Thermo Fisher Scientific Inc |
5.51 0.80% |
692.30 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
0.17 0.07% |
228.58 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
25.06 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.38 1.56% |
23.97 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
No. 5, Xingdao Ring Road North, Guangzhou, China, 510005
86 20 3403 7871
667
| Name | Title | Year Born |
|---|---|---|
| Dr. Shaokun Chuai | Chief Scientific Officer & Director | 1979 |
| Mr. Yusheng Han | Founder, Chairman & CEO | 1979 |
| Mr. Jinxiang Li | CFO, Compliance Officer & Director | 1985 |
| Dr. Zhihong Zhang | Chief Technology Officer | 1976 |
| Mr. Hao Liu | Sr. Advisor | 1974 |
| Dr. Zhihong Zhang | CTO & Director | 1976 |
| Mr. Hao Liu | Senior Advisor | 1974 |
| Ms. Xiaozhi Hu | Senior Director of Finance | 1984 |
| Dr. Xinru Mao | Head of Pharma Biomarker & CDx Service and International Diagnostics Division | NA |
| Ms. Xiaozhi Hu | Vice President of Finance | 1984 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.